Last reviewed · How we verify
Proflavine Hemisulfate — Competitive Intelligence Brief
marketed
Acridine dye; DNA intercalating agent
DNA (non-specific intercalation)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Proflavine Hemisulfate (Proflavine Hemisulfate) — M.D. Anderson Cancer Center. Proflavine hemisulfate is an acridine dye that intercalates into DNA and generates reactive oxygen species, causing direct antimicrobial and antiproliferative effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Proflavine Hemisulfate TARGET | Proflavine Hemisulfate | M.D. Anderson Cancer Center | marketed | Acridine dye; DNA intercalating agent | DNA (non-specific intercalation) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Acridine dye; DNA intercalating agent class)
- M.D. Anderson Cancer Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Proflavine Hemisulfate CI watch — RSS
- Proflavine Hemisulfate CI watch — Atom
- Proflavine Hemisulfate CI watch — JSON
- Proflavine Hemisulfate alone — RSS
- Whole Acridine dye; DNA intercalating agent class — RSS
Cite this brief
Drug Landscape (2026). Proflavine Hemisulfate — Competitive Intelligence Brief. https://druglandscape.com/ci/proflavine-hemisulfate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab